Edesa Biotech (EDSA) Jumps Amid Future Use Of EB05 Drug For Phase 2/3 Clinical Study To Treat COVID-19 Patients

As FSD Pharma (NASDAQ: HUGE), Edesa Biotech (NASDAQ: EDSA) soars more than 100% in premarket after announcing a filing IND application for Phase 2/3 clinical trials of its EB05 vaccine to treat COVID-19 victims.

At the beginning of June NASDAQ: EDSA could grow significantly from $2.90 to $5.87 due to studying its drugs to treat COVID-19 patients. Several biotech stocks grew in the same way but their volatilities are very steep.

Before EDSA gets a huge price higher than $100 risk-loving traders may try their lucks on this stock. However, its EPS may become positive in next quarter results, gradually long term goal settlers might buy its shares as well.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life